DDInter119 DDInter785
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Fostamatinib may lead to a major life threatening interaction when taken with Clarithromycin
Fostamatinib may lead to a major life threatening interaction when taken with Berotralstat